On the 18th, the Incheon Free Economic Zone Authority announced that the biopharmaceutical production capacity in Songdo International City has surpassed 1 million liters annually. This capacity has gradually increased from 50,000 liters in 2010 to 330,000 liters in 2015 and 560,000 liters in 2020. However, projections indicate a remarkable surge to approximately 1.04 million liters by 2025, with estimates for this year's production capacity expected to reach 1.16 million liters.

The sharp increase in production capacity is significantly attributed to the newly opened facilities, including Celltrion's third plant, which began commercial production in 2024 with the ability to produce 60,000 liters, and Samsung Biologics' fifth plant, operational since last year, which has a capacity of 180,000 liters. The completion of Lotte Biologics' first plant at the Songdo Bio Campus by the end of this year is also expected to add an additional 120,000 liters of production capacity. Future expansions are also on the horizon, with Samsung Biologics planning to complete its second biocampus by 2032, which will further enhance capacity to 1.325 million liters.

Additionally, other companies like SK Bioscience are moving their headquarters and research facilities to Songdo, while the German biopharmaceutical raw material firm Sartorius Korea Operations plans to establish production and research facilities by 2027. The Acting Commissioner of the Incheon Free Economic Zone Authority, Hong Joon-ho, remarked that Incheon is evolving from being merely the largest biopharmaceutical production base in the world to becoming a hub for biopharmaceutical innovation.